Over a week ago |
Hot Stocks
|
Editas Medicine announced… Editas Medicine announced that it has entered into a definitive agreement with Shoreline Biosciences for Shoreline to license Editas Medicine's proprietary SLEEK and AsCas12a gene editing technologies and acquire Editas Medicine's preclinical gene edited induced pluripotent stem cell derived natural killer cell programs and related manufacturing technologies. Shoreline Biosciences is a private biopharmaceutical company developing next-generation cellular immunotherapies based on iPSCs utilizing proprietary iNK and macrophage platforms. Under the terms of the agreement, Shoreline will obtain an exclusive license to Editas Medicine's interest in SLEEK gene editing knock-in technology for use in Shoreline's iNK platform and for oncology in its iMACs platform, and on a non-exclusive basis for iMACs in other indications. Shoreline will also receive a non-exclusive license for the use of Editas Medicine's engineered AsCas12a enzyme. As part of the transaction, Shoreline will acquire EDIT-202, Editas Medicine's preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors, as well as an additional iNK program under development and certain related manufacturing technologies. The acquisition of the Company's wholly owned oncology assets by Shoreline is part of Editas Medicine's strategic portfolio reprioritization, including its focus on the development of in vivo gene edited medicines. Shoreline will pay Editas Medicine an upfront payment at the close of the transaction. Additionally, Editas Medicine is eligible to receive future development and commercial milestone and royalty payments for each of the iNK programs and for future programs engineered with the gene editing technologies. Evercore Group LLC served as financial advisor to Editas Medicine on the transaction. ShowHide Related Items >><< - 01/09/23
- Editas Medicine provides update, to reduce headcount by approximately 20%
- 12/06/22
- Editas Medicine's EDIT-301 shows safety and efficacy in sickle cell disease
- 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 12/13/22 Citi
- Editas Medicine initiated with a Neutral at Citi
- 12/05/22 Credit Suisse
- Editas Medicine assumed with a Neutral at Credit Suisse
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Hot Stocks
|
Editas Medicine announced… Editas Medicine announced a strategic update, including portfolio reprioritization and research and development realignment. The Company's R&D efforts will narrow, focusing on hemoglobinopathies and in vivo discovery, as Editas Medicine will pursue and develop programs it believes have maximum probabilities of technical, regulatory, and commercial success. As a result of the strategic reprioritization, Editas Medicine's headcount is being reduced by approximately 20%, which is expected to extend the Company's cash runway into 2025. Editas Medicine's strategic changes include: Prioritizing resource allocation towards EDIT-301, the Company's lead clinical program for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. Discontinuing internal investments in the Company's inherited retinal disease programs, including EDIT-101 for Leber Congenital Amaurosis 10 and EDIT-103 for rhodopsin-associated autosomal dominant retinitis pigmentosa. Editas Medicine will seek partnerships for further development of its IRD programs. Discontinuing internal investments in the Company's wholly owned multiplexed edited induced pluripotent stem cell derived natural killer cell programs, including EDIT-202 for solid tumors. Editas Medicine will seek a partnership to continue development of the Company's iNK franchise. Restructuring the Company's research organization into two divisions: Drug Discovery for in vivo target identification, therapeutic asset creation, and translational research. Advanced Technology for in vivo targeted integration and targeted delivery. Developing milder patient preconditioning regimens for hematopoietic stem cell transplants. Developing next generation in vivo medicines, including in vivo editing of HSCs and other tissues. Editas Medicine will continue advancing its cellular therapy assets through partnerships, including continued development of alpha-beta T-cell medicines with Bristol-Myers-Squibb and gamma-delta T-cell medicines with Immatics N.V. The Company will also continue assessing additional collaboration opportunities to license Editas Medicine's intellectual property and proprietary technology. ShowHide Related Items >><< - 12/06/22
- Editas Medicine's EDIT-301 shows safety and efficacy in sickle cell disease
- 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 12/13/22 Citi
- Editas Medicine initiated with a Neutral at Citi
- 12/05/22 Credit Suisse
- Editas Medicine assumed with a Neutral at Credit Suisse
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Over a month ago |
Initiation
|
Citi analyst Samantha… Citi analyst Samantha Semenkow initiated coverage of Editas Medicine with a Neutral rating and $11 price target. The clinical-stage biotech company's CRISPR technology has "the potential to be transformative across multiple genetic diseases," but Editas has faced several leadership challenges and pipeline execution has lagged peers, Semenkow tells investors. The market was already fairly valuing EDIT-301 and pausing development of EDIT-101 in LCA10 has potential readthrough on feasibility for the remaining ophthalmology pipeline, said Semenkow, who expects shares to remain pressured. ShowHide Related Items >><< - 12/06/22
- Editas Medicine's EDIT-301 shows safety and efficacy in sickle cell disease
- 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 12/05/22 Credit Suisse
- Editas Medicine assumed with a Neutral at Credit Suisse
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/18/22 RBC Capital
- Editas Medicine price target lowered to $14 from $32 at RBC Capital
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Conference/Events
|
Conference call to… Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link ShowHide Related Items >><< - 12/06/22
- Editas Medicine's EDIT-301 shows safety and efficacy in sickle cell disease
- 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 12/05/22 Credit Suisse
- Editas Medicine assumed with a Neutral at Credit Suisse
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/18/22 RBC Capital
- Editas Medicine price target lowered to $14 from $32 at RBC Capital
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Hot Stocks
|
Editas Medicine announced… Editas Medicine announced "positive" initial clinical data from the first two patients with sickle cell disease treated with EDIT-301 in the Phase 1/2 RUBY trial. EDIT-301 is under development for the treatment of severe sickle cell disease. The clinical data includes safety data from the first two patients and efficacy data from the first patient treated. Both treated patients demonstrated successful neutrophil and platelet engraftment. Patient 1 achieved neutrophil engraftment at 23 days after EDIT-301 infusion and platelet engraftment at 19 days after EDIT-301 infusion. Patient 2 achieved neutrophil engraftment 29 days after EDIT-301 infusion and platelet engraftment 37 days after EDIT-301 infusion. Additionally, neither patient has experienced any vaso-occlusive events since treatment with EDIT-301, at five and 1.5 months follow up, respectively. At five months post-treatment, the first patient treated with EDIT-301 has a total hemoglobin of 16.4 g/dL, a fetal hemoglobin (or HbF) of 45.4%, and a mean corpuscular HbF of 13.8 pg/red blood cell, exceeding the 10.0 pg/red blood cell threshold to suppress red blood cell sickling. Additionally, HbF increase in the first patient was highly pancellular, with F cells steadily increasing to reach greater than 95% of red blood cells. EDIT-301 was well-tolerated in the two patients and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. No serious adverse events occurred, and no adverse events reported were related to treatment with EDIT-301. The company expects to share further clinical updates in mid-2023. ShowHide Related Items >><< - 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 10/13/22
- Editas Medicine presents preclinical data on EDIT-103 for RHO-adRP
- 12/05/22 Credit Suisse
- Editas Medicine assumed with a Neutral at Credit Suisse
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/18/22 RBC Capital
- Editas Medicine price target lowered to $14 from $32 at RBC Capital
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Conference/Events
|
Conference call to… Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link ShowHide Related Items >><< - 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 10/13/22
- Editas Medicine presents preclinical data on EDIT-103 for RHO-adRP
- 12/05/22 Credit Suisse
- Editas Medicine assumed with a Neutral at Credit Suisse
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/18/22 RBC Capital
- Editas Medicine price target lowered to $14 from $32 at RBC Capital
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Conference/Events
|
Conference call to… Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link ShowHide Related Items >><< - 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 10/13/22
- Editas Medicine presents preclinical data on EDIT-103 for RHO-adRP
- 12/05/22 Credit Suisse
- Editas Medicine assumed with a Neutral at Credit Suisse
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/18/22 RBC Capital
- Editas Medicine price target lowered to $14 from $32 at RBC Capital
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
Initiation
|
Credit Suisse analyst… Credit Suisse analyst Richard Law assumed coverage of Editas Medicine with a Neutral rating and $13 price target. The analyst states that he is assuming a 70% probability of favorable final appeal ruling for Broad/MIT from the U.S. federal appeals court, which would give the company "monopolistic IP control of CRISPR/Cas9 editing in the U.S." Law further notes that he assigns "little value" to Editas' lead asset EDIT-301 as he does not believe that the company could demonstrate differentiated benefits that are "clinically meaningful". ShowHide Related Items >><< - 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 10/13/22
- Editas Medicine presents preclinical data on EDIT-103 for RHO-adRP
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/18/22 RBC Capital
- Editas Medicine price target lowered to $14 from $32 at RBC Capital
- 11/18/22 Truist
- Editas Medicine price target lowered to $35 from $80 at Truist
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
|
On The Fly
| ShowHide Related Items >><< - 11/16/22
- Roche receives FDA Emergency Use Authorization for test to detect monkeypox
- 11/15/22
- Roche enters second collaboration, license agreement with Jnana
- 11/14/22
- Roche gets FDA approval for VENTANA FOLR1 assay for ELAHERE treatment
- 11/14/22
- Genentech announces GRADUATE I, II studies miss primary endpoints
- 11/11/22
- Regeneron and Sanofi's Dupixent recommended for EU approval in prurigo nodularis
- 11/11/22
- Regeneron, Sanofi announce CHMP recommendation for Dupixent approval
- 11/09/22
- USPTO board says Mylan has shown claims of Regeneron patent 'unpatentable'
LCTX Lineage Cell Therapeutics - 10/31/22
- Lineage Cell Therapeutics announces Jill Howe joins as CFO
- 10/10/22
- Lineage announces Notice of Allowance from USPTO for specific cell production
- 08/11/22
- Lineage Cell Therapeutics expects cash to fund operations through Q2 of 2024
- 11/17/22
- Immunic reports new data from EMPhASIS trial of vidofludimus calcium
- 10/24/22
- Point72 Capital reports 4.9% passive stake in Immunic
- 10/21/22
- Commodore Capital reports 9.3% passive stake in Immunic
- 10/20/22
- Immunic falls 78% after Phase 1b IMU-935 update saw no separation from placebo
- 11/17/22
- Editas sinks 17% to $10.11 after pausing BRILLIANCE study enrollment
- 11/17/22
- Editas Medicine announces clinical data from Phase 1/2 BRILLIANCE trial
- 10/18/22
- Editas Medicine rises after report of talks to sell preclinical oncology assets
- 10/13/22
- Editas Medicine presents preclinical data on EDIT-103 for RHO-adRP
- 11/17/22
- Regeneron, CytomX Therapeutics announce research collaboration
- 09/12/22
- CytomX Therapeutics announces Phase 1 data for anti-CTLA-4 probody
- 07/13/22
- CytomX Therapeutics to restructure business, reduce workforce by 40%
- 07/06/22
- CytomX Therapeutics trading resumes
- 11/07/22
- Supreme Court rejects Bristol-Myers appeal of patent ruling, Reuters reports
- 11/03/22
- Kura Oncology enters financing transactions with Bristol-Myers Hercules Capital
- 10/31/22
- Bristol-Myers' MDS candidate Reblozyl meets primary and secondary endpoints
- 10/27/22
- Obsidian Therapeutics announces extension of agreement with Bristol-Myers
- 11/09/22
- Royalty Pharma agrees to acquire royalty interest in olpasiran from Arrowhead
- 11/09/22
- Arrowhead sells royalty interest in olpasiran to Royalty Pharma for $250M+
- 11/07/22
- Amgen presents new Repatha data at AHA 2022
- 11/06/22
- Amgen presents end-of-treatment data from Phase 2 OCEAN(a)-DOSE study
AGIO Agios Pharmaceuticals - 11/03/22
- Agios Pharmaceuticals expects cash to fund operations through catalysts
- 10/27/22
- Agios sells 5% royalties on Tibsovo U.S. sales to Sagard for $131.8M
- 09/19/22
- Agios Pharmaceuticals appoints Cecilia Jones as CFO
- 09/16/22
- Agios Pharmaceuticals receives positive CHMP opinion for PYRUKYND
- 11/21/22
- AbbVie: FDA accepts for priority review BLA for epcoritamab
- 11/07/22
- AbbVie: Primary endpoint not met for mITT population in NOVA phase 2 trial
- 10/28/22
- AbbVie expects Humira access for at least 80% of U.S. insured
- 10/28/22
- AbbVie says seeing slowdown in aesthetic procedures due to inflation
- 11/14/22 BMO Capital
- CytomX Therapeutics downgraded to Market Perform from Outperform at BMO Capital
- 11/10/22 JPMorgan
- JPMorgan double downgrades 'show-me-story' CytomX Therapeutics
- 11/10/22 JPMorgan
- CytomX Therapeutics downgraded to Underweight from Overweight at JPMorgan
- 07/11/22 Cowen
- CytomX Therapeutics downgraded to Market Perform from Outperform at Cowen
AGIO Agios Pharmaceuticals - 11/17/22 Goldman Sachs
- Agios Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
- 07/27/22 SVB Securities
- Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
- 02/25/22 RBC Capital
- Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital
- 02/24/22 H.C. Wainwright
- Agios Pharmaceuticals price target lowered to $96 from $98 at H.C. Wainwright
LCTX Lineage Cell Therapeutics - 11/01/22 Baird
- Baird starts Lineage Cell Therapeutics with an Outperform, $5 price target
- 11/01/22 Baird
- Lineage Cell Therapeutics initiated with an Outperform at Baird
- 06/14/22 B. Riley
- B. Riley starts 'deep value play' Lineage Cell with Buy, $4 target
- 06/14/22 B. Riley
- Lineage Cell Therapeutics initiated with a Buy at B. Riley
- 11/18/22 Morgan Stanley
- Editas Medicine price target lowered to $8 from $10 at Morgan Stanley
- 11/18/22 BofA
- Editas' EDIT-101 setback 'not the end of the story,' says BofA
- 11/18/22 RBC Capital
- Editas Medicine price target lowered to $14 from $32 at RBC Capital
- 11/18/22 Truist
- Editas Medicine price target lowered to $35 from $80 at Truist
- 10/21/22 SVB Securities
- Immunic downgraded to Market Perform from Outperform at SVB Securities
- 09/19/22 H.C. Wainwright
- Immunic assumed with a Buy at H.C. Wainwright
- 06/02/22 Roth MKM
- Roth suggests accumulating Immunic shares on pullback
- 06/02/22 Wedbush
- Immunic price target lowered to $14 from $61 at Wedbush
- 11/17/22 Credit Suisse
- AbbVie initiated with an Outperform at Credit Suisse
- 11/08/22 Societe Generale
- AbbVie downgraded at Societe Generale on blood cancer and aesthetics headwinds
- 11/08/22 Societe Generale
- AbbVie downgraded to Hold from Buy at Societe Generale
- 10/28/22 Piper Sandler
- Piper keeps Overweight rating on AbbVie despite 'rough' Q3 report
- 11/17/22 Credit Suisse
- Bristol-Myers initiated with a Neutral at Credit Suisse
- 11/17/22 Morgan Stanley
- Ventyx Biosciences initiated with an Overweight at Morgan Stanley
- 11/02/22 Evercore ISI
- Evercore starts Legend Biotech with an Outperform on Carvykti potential
- 11/17/22 Credit Suisse
- Amgen initiated with an Underperform at Credit Suisse
- 11/08/22 Oppenheimer
- Amgen price target raised to $300 from $290 at Oppenheimer
- 11/08/22 Truist
- Amgen price target raised to $280 from $266 at Truist
- 11/04/22 Piper Sandler
- Amgen price target raised to $278 from $265 at Piper Sandler
- 11/15/22 Truist
- Biogen price target raised to $350 from $265 at Truist
- 11/15/22 Truist
- Eli Lilly price target raised to $421 from $400 at Truist
- 11/15/22 Stifel
- Roche downgraded to Hold from Buy at Stifel
- 11/15/22 Cowen
- Roche downgraded to Market Perform on 'bare' pipeline at Cowen
- 11/09/22 RBC Capital
- Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
- 11/09/22 Truist
- Regeneron price target raised to $856 from $790 at Truist
- 11/03/22 Piper Sandler
- Regeneron price target lowered to $765 from $775 at Piper Sandler
- 10/31/22 EF Hutton
- Regeneron initiated with a Buy at EF Hutton
- 10/18/22
- Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year
- 07/21/22
- Roche reports 1H core EPS CHF 11.76 vs. CHF 10.56 last year
- 11/03/22
- Regeneron reports Q3 EPS $11.14, consensus $9.48
- 11/02/22
- Notable companies reporting before tomorrow's open
- 08/03/22
- Regeneron reports Q2 EPS $9.77, consensus $9.54
LCTX Lineage Cell Therapeutics - 08/11/22
- Lineage Cell Therapeutics reports Q2 EPS (4c), consensus (4c)
- 08/04/22
- Immunic reports Q2 EPS (72c), consensus (72c)
- 11/02/22
- Editas Medicine reports Q3 EPS (81c), consensus (86c)
- 08/03/22
- Editas Medicine reports Q2 EPS (78c), consensus (82c)
- 11/08/22
- CytomX Therapeutics reports Q3 EPS (35), consensus (31c)
- 08/04/22
- CytomX Therapeutics reports Q2 EPS (37c), consensus (36c)
- 10/25/22
- Notable companies reporting before tomorrow's open
- 10/25/22
- Bristol-Myers affirms FY22 EPS view of $7.44 - $7.74, consensus $7.51
- 10/25/22
- Bristol-Myers reports Q3 EPS $1.99, consensus $1.83
- 11/03/22
- Amgen narrows FY22 adjusted EPS view to $17.25-$17.85 from $17.00-$18.00
- 11/03/22
- Amgen reports Q3 adjusted EPS $4.70, consensus $4.44
- 11/03/22
- Notable companies reporting after market close
- 08/04/22
- Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.40
AGIO Agios Pharmaceuticals - 11/03/22
- Agios Pharmaceuticals reports Q3 EPS ($1.49), consensus ($1.76)
- 08/04/22
- Agios Pharmaceuticals reports Q2 EPS ($1.68), consensus ($1.75)
- 11/08/22
- Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
- 10/28/22
- AbbVie sees FY22 revenue approximately $58.2B, consensus $59.92B
- 10/28/22
- AbbVie sees Q4 adjusted EPS $3.65-$3.69, consensus $3.75
- 10/28/22
- AbbVie narrows FY22 adjusted EPS view to $13.84-$13.88 from $13.76-$13.96
- 09/16/22
- WHO panel recommends against GSK, Regeneron COVID drugs, Bloomberg reports
- 10/18/22
- Editas in talks to sell preclinical oncology assets, Endpoints News says
- 07/25/22
- Researchers warn CRISPR gene editing may trigger cancer, Jerusalem Post says
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 06/24/22
- Judge says Bristol-Myers must face $6.4B Breyanzi lawsuit, Reuters says
- 06/14/22
- FTC asked to investigate price hikes by Janssen, Bristol-Myers, STAT says
- 05/28/22
- Buy Bristol-Myers, rally just getting started, Barron's says
- 11/04/22
- Supreme Court to hear Amgen appeal in Repatha patent dispute, Bloomberg says
- 08/01/22
- Amgen battles IRS over $10.7B in back taxes, WSJ reports
- 11/16/22
- Optum Rx puts biosimilars on formulary against AbbVie's Humira, Bloomberg says
- 07/27/22
- AbbVie unit Allergan settles opioid cases for over $2B, Bloomberg reports
- 11/16/22
- Biotech Alert: Searches spiking for these stocks today
- 11/15/22
- Biotech Alert: Searches spiking for these stocks today
- 11/14/22
- What You Missed On Wall Street On Monday
- 10/29/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 10/26/22
- What You Missed On Wall Street This Morning
LCTX Lineage Cell Therapeutics - 06/14/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/21/22
- What You Missed On Wall Street On Friday
- 10/21/22
- What You Missed On Wall Street This Morning
- 10/21/22
- Fly Intel: Pre-market Movers
- 11/18/22
- What You Missed On Wall Street On Friday
- 11/18/22
- What You Missed On Wall Street This Morning
- 11/18/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/21/22
- Biotech Alert: Searches spiking for these stocks today
- 11/10/22
- What You Missed On Wall Street On Thursday
- 11/10/22
- What You Missed On Wall Street This Morning
- 11/10/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/17/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/10/22
- Meet Silo Pharma: Fly exclusive interview with CEO Weisblum, VP of R&D Kuo
- 10/26/22
- What You Missed On Wall Street On Wednesday
- 11/08/22
- What You Missed On Wall Street On Tuesday
- 11/08/22
- What You Missed On Wall Street This Morning
- 10/11/22
- What You Missed On Wall Street On Tuesday
- 11/16/22
- What You Missed On Wall Street This Morning
- 10/28/22
- What You Missed On Wall Street On Friday
- 10/28/22
- What You Missed On Wall Street This Morning
- 09/16/22
- Early notable gainers among liquid option names on September 16th
- 09/09/22
- Early notable gainers among liquid option names on September 9th
- 09/08/22
- Early notable gainers among liquid option names on September 8th
- 08/03/22
- Early notable gainers among liquid option names on August 3rd
- 11/01/22
- Largest borrow rate increases among liquid names
- 10/28/22
- Largest borrow rate increases among liquid names
- 10/27/22
- Largest borrow rate increases among liquid names
- 10/26/22
- Largest borrow rate increases among liquid names
- 09/29/22
- Early notable gainers among liquid option names on September 29th
- 09/12/22
- Early notable gainers among liquid option names on September 12th
- 09/12/22
- Unusually active option classes on open September 12th
- 09/08/22
- Notable open interest changes for September 8th
- 10/11/22
- Early notable gainers among liquid option names on October 11th
- 07/12/22
- Amgen put volume heavy and directionally bearish
- 06/27/22
- Amgen put volume heavy and directionally bearish
- 10/28/22
- Unusually active option classes on open October 28th
- 08/19/22
- Unusually active option classes on open August 19th
|